Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Cited by (1,000)

Items 201–300 of 1,000

1. Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
   Robert A. Heald, Krista K. Bowman, Marian C. Bryan, Daniel J. Burdick, Bryan K. Chan, Emily W. Chan, Yuan Chen, Saundra Clausen, Belen Dominguez‐Fernandez, Charles W. Eigenbrot et al. · 2015 · Journal of Medicinal Chemistry
2. Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells
   Li Qun Zhou, Ming Li, Xinyou Yu, Feng Gao, Wei Li · 2019 · International Journal of Biological Sciences
3. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer
   Simone Gastaldi, Francesco Paolo Sassi, Paolo Accornero, Davide Torti, Francesco Galimi, Giorgia Migliardi, Gemma Molyneux, Timothy Pietro Suren Perera, Paolo Maria Comoglio, Carla Boccaccio et al. · 2012 · Oncogene
4. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
   Zeng, Hao, Castillo-Cabrera, Johnny, Manser, Mika, Lu, Bo, Yang, Zinger, Strande, Vaik, Begue, Damien, Zamponi, Raffaella, Qiu, Shumei, Sigoillot, Frederic et al. · 2019 · eLife
5. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
   Andreas N. WICKI, Mario Mandalà, Daniela Massi, Daniela Taverna, Huifang Tang, Brian A. Hemmings, Gongda Xue · 2016 · Physiological Reviews
6. Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
   Fengxiang Wei, Jenny Jiacheng Yan, Damu Tang · 2011 · Current Medicinal Chemistry
7. Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition
   Chung Choe, Yong-Sung Shin, So‐Jung Choi, Jinseon Lee, So Young Kim, Yong Beom Cho, Jhingook Kim, Changhoon Kim · 2015 · OncoTargets and Therapy
8. Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
   Johannes M. Heuckmann, Daniel Rauh, Roman Kurt Thomas · 2012 · Journal of Clinical Oncology
9. Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
   Shannon M. Mumenthaler, Jasmine Foo, Kevin Leder, Nathan C. Choi, David B. Agus, William J. Pao, Parag Mallick, Franziska Michor A · 2011 · Molecular Pharmaceutics
10. Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
    Taishi Harada, Yasushi Yatabe, Masafumi Takeshita, Takaomi Koga, Tokujiro Yano, Yisong Wang, Giuseppe Giaccone · 2011 · Clinical Cancer Research
11. Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90–EGFR association
    YC Yang, T-Y Cheng, S-M Huang, Chia‐Yi Su, P-W Yang, J-M Lee, C-K Chen, Michael Hsiao, K-T Hua, M-L Kuo · 2015 · Oncogene
12. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
    Krishna Babu Duggirala, Yujin Lee, Kwangho Lee · 2021 · Biomolecules & Therapeutics
13. Automated tumor analysis for molecular profiling in lung cancer
    Peter W. Hamilton, Yinhai Wang, Clinton Boyd, Jacqueline A. James, Maurice Bernard Loughrey, Joseph P. Hougton, David P. Boyle, Paul Kelly, Perry Maxwell, David F. McCleary et al. · 2015 · Oncotarget
14. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
    Paolo Maione, Paola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, Antônio Rossi, Cesare Gridelli · 2015 · Therapeutic Advances in Medical Oncology
15. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
    Hannah A. Scarborough, Barbara A. Helfrich, Matias Casás‐Selves, Alwin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik Choon Tan, Daniel C. F. Chan, Zhiyong Zhang, Vadym Zaberezhnyy et al. · 2016 · Clinical Cancer Research
16. Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion
    Joon Hee Kang, Seon-Hyeong Lee, Jae‐Seon Lee, Boas Nam, Tae Wha Seong, Jaekyoung Son, Hyonchol Jang, Kyeong Man Hong, Cheolju Lee, Soo‐Youl Kim · 2016 · Oncotarget
17. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
    Jacqueline H. Starrett, Alexis A. Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy L. Nagelberg, Dylan Farnsworth, Kristin Sedgwick Price, Hina Khan, Kumar Dilip Ashtekar et al. · 2020 · Cancer Research
18. Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion
    Timothy G. Whitsett, Emily Cheng, Landon J. Inge, Kaushal V. Asrani, Nathan M. Jameson, Galen H. Hostetter, Glen J. Weiss, Christopher B. Kingsley, Joseph C. Loftus, Ross Macrae Bremner et al. · 2012 · American Journal Of Pathology
19. Role of Fluorescence in situ Hybridization in Lung Cancer Cytology
    Spasenija Savic, Lukas Bubendorf · 2012 · Acta Cytologica
20. Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis
    Xiao-Hong Kang, Zhen-Ye Xu, Ya-Bin Gong, Li‐Fang Wang, ZhongQi Wang, Ling Xu, Fei Cao, Ming-juan Liao · 2013 · Evidence-based Complementary and Alternative Medicine
21. c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
    Aijun Shen, Lu Wang, Min Huang, Jingya Sun, Yi Chen, Yanyan Shen, Xinying Yang, Xin Wang, Jian Ding, Meiyu Geng · 2015 · Cancer Research
22. Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
    Yoon Soo Chang, Chang‐Min Choi, Jae Cheol Lee · 2016 · Tuberculosis & respiratory diseases
23. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer
    Kaixian Zhang, Qianqian Yuan · 2016 · Journal of Cancer Research and Therapeutics
24. Inhibitors of the anaplastic lymphoma kinase
    Luca Mologni · 2012 · Expert Opinion on Investigational Drugs
25. CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors
    Masayuki Ishibashi, Shinya Neri, Hiroko Hashimoto, Tomoyuki Miyashita, Tatsuya Yoshida, Yuka Nakamura, Hibiki Udagawa, Keisuke Kirita, Shingo Matsumoto, Shigeki Umemura et al. · 2017 · Scientific Reports
26. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
    Judith N. Müller, Markus Falk, Jatin Talwar, Nicole Neemann, Erika Mariotti, Miriam Bertrand, Tobias Zacherle, Sotirios Lakis, Roopika Menon, Christian Gloeckner et al. · 2017 · Journal of Thoracic Oncology
27. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization
    Feng Gao, Xinfang Yu, Ming Li, Li Qun Zhou, Wenbin Liu, Wěi Li, Haidan Liu · 2020 · Cell Death and Disease
28. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines
    Liangkun You, Jiawei Shou, Danchen Deng, Liming Jiang, Jing Zhao, Junlin Yao, Hongsen Li, Jiansheng Xie, Zhanggui Wang, Pan Qin et al. · 2015 · Oncotarget
29. Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer
    Alexandra B. Lantermann, Dongshu Chen, Kaitlin McCutcheon, Greg Hoffman, Elizabeth Frias, David A. Ruddy, Daniel P. Rakiec, Joshua M. Korn, Gregory McAllister, Frank P. Stegmeier et al. · 2015 · Cancer Research
30. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
    Jinrong Liao, Jinghui Lin, Dong xian Lin, Changyan Zou, Jessica S. Kurata, Ren-Jang Lin, Zhiyong He, Ying Su · 2017 · Scientific Reports
31. Acid-sensing ion channels contribute to the effect of extracellular acidosis on proliferation and migration of A549 cells
    Yu Cheng Wu, Bo Gao, Qiuju Xiong, Yuchan Wang, Dake Huang, Wen‐Ning Wu · 2017 · Tumor Biology
32. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
    Yan Zhang, Cheng Xiang, Yuling Wang, Yuanyuan Duan, Ci Liu, Yajing Zhang · 2017 · Oncotarget
33. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
    Zheng-Hai Tang, Xiaoming Jiang, Xia Guo, Chi Man Vivienne Fong, Xiuping Chen, Jin‐Jian Lu · 2016 · Oncotarget
34. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
    Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong‐Mu Sun, Yoon‐La Choi, Se‐Hoon Lee, Jin Seok Ahn et al. · 2018 · Cancer Research and Treatment
35. Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation
    Yosuke Togashi, Hidetoshi Hayashi, Masato Terashima, Marco Antonio De Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Kazuhiko Nakagawa, Kazuto Nishio · 2014 · Journal of Thoracic Oncology
36. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer
    Fernando López‐Ríos, Bárbara Angulo, Belen Gomez, Debbie Mair, Rebeca Martínez, Esther Conde, Felice Shieh, Julie Tsai, Jeffrey E. Vaks, Robert Current et al. · 2013 · Journal of Clinical Pathology
37. Characteristics of lung cancer in women: Importance of hormonal and growth factors
    Isabelle Rouquette, Valérie Lauwers‐Cancès, Camille Allera-Moreau, Laurent Brouchet, Julie Milia, Yvan Nicaise, Julie Laurent, Marie‐Bernadette Delisle, Gilles Favre, Alain P. Didier et al. · 2011 · Lung Cancer
38. Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
    Chao Ding, Shaopeng Chen, Cunlong Zhang, Guangnan Hu, Wei Zhang, Lulu Li, Yu Chen, Chunyan Tan, Yuyang Jiang · 2016 · Bioorganic & Medicinal Chemistry
39. 3D‐Printed Polypropylene Continuous‐Flow Column Reactors: Exploration of Reactor Utility in SNAr Reactions and the Synthesis of Bicyclic and Tetracyclic Heterocycles
    Zenobia X. Rao, Bhaven Patel, Alessandra Monaco, Zi Jing Cao, Marta Barniol‐Xicota, Enora Pichon, Mark Ladlow, Stephen T. Hilton · 2017 · European Journal of Organic Chemistry
40. Collagen type I induces EGFR ‐ TKI resistance in EGFR ‐mutated cancer cells by mTOR activation through Akt‐independent pathway
    Shota Yamazaki, Youichi Higuchi, Masayuki Ishibashi, Hiroko Hashimoto, Masahiro Yasunaga, Yasuhiro Matsumura, Katsuya Tsuchihara, Masahiro Tsuboi, Kōichi Goto, Atsushi Ochiai et al. · 2018 · Cancer Science
41. TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
    Surui Liu, Jin Seok Yu, Hui Zhang, Jie Liu · 2022 · Frontiers in Oncology
42. Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer
    Jean‐Yves Douillard, Robert Pirker, Kenneth John O'Byrne, Keith M. Kerr, Stephan Störkel, Anja von Heydebreck, Hans Jürgen Grote, Ilhan Celik, Frances A. Shepherd · 2014 · Journal of Thoracic Oncology
43. Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making
    Roser Pinyol, Jean‐Charles Nault, Iris M. Quetglas, Jessica Zucman‐Rossi, Josep Maria Llovet · 2014 · Seminars in Liver Disease
44. Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component
    Paul K. Paik, Anna M. Varghese, Camelia S. Sima, Andre Luis Moreira, Marc Ladanyi, Mark G. Kris, Natasha Rekhtman · 2012 · Molecular Cancer Therapeutics
45. Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor
    Xiongwei Xu, Xiuhua Weng, Changlian Wang, Wei-Wei Lin, Ai‐Lin Liu, Wei Chen, Xinhua Lin · 2016 · Biosensors and Bioelectronics
46. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3
    Jiawei Shou, Liangkun You, Junlin Yao, Jiansheng Xie, Jing Jing, Jing Zhao, Liming Jiang, Xinbing Sui, Hongming Pan, Weidong Han · 2016 · Cancer Letters
47. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines
    Valentina Fustaino, Dario Presutti, Teresa Colombo, Beatrice Cardinali, Giuliana Papoff, Rossella Brandi, Paola Bertolazzi, Giovanni Felici, Giovina Ruberti · 2017 · Oncotarget
48. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
    Nan Yao, Chenran Wang, Mingqun Liu, Yingjie Li, Wei‐Min Chen, Zhengqiu Li, Qi Qi, Jin‐Jian Lu, Chun-Lin Fan, Minfeng Chen et al. · 2020 · Signal Transduction and Targeted Therapy
49. Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
    Sung Hee Lim, Ji Yun Lee, Jong‐Mu Sun, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2014 · Journal of Thoracic Oncology
50. In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics
    Ida Grundberg, Sara Kiflemariam, Marco Mignardi, Juliana Imgenberg‐Kreuz, Karolina Edlund, Patrick Micke, Magnus Sundström, Tobias Sjöblom, Johan Botling, Mats F. Nilsson · 2013 · Oncotarget
51. Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
    Jackie L. Johnson, Smitha Pillai, Srikumar Chellappan · 2012 · Biochemistry Research International
52. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC)
    JORDAN P. REYNOLDS, Raymond R. Tubbs, Eugen C. Minca, Stephen MacNamara, Francisco Aécio Almeida, Patrick C. Ma, Nathan A. Pennell, Joseph C. Cicenia · 2014 · Lung Cancer
53. RNA is favourable for analysingEGFRmutations in malignant pleural effusion of lung cancer
    T-H. Tsai, Kang‐Yi Su, Shang‐Gin Wu, Yih‐Leong Chang, Shunqun Luo, I‐Shiow Jan, Chong‐Jen Yu, S.-L. Yu, J-Y. Shih, Pan‐Chyr Yang · 2011 · European Respiratory Journal
54. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review
    Michael Yamakawa, Susan J. Doh, Samuel M. Santosa, Mario Montana, Ellen C. Qin, Hyunjoon Kong, Kyu‐Yeon Han, Charles Q. Yu, Mark I. Rosenblatt, Andrius Kazlauskas et al. · 2018 · Medicinal Research Reviews
55. Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
    Jennifer Wilkinson Carlisle, Suresh S. Ramalingam · 2019 · Future Oncology
56. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non–small cell lung cancer
    Ke Li, Xufen Zheng, Hua Tang, Yuan‐Sheng Zang, Chunling Zeng, Xiaoxiao Liu, Yanying Shen, Yuzhi Pang, Simin Wang, Feifei Xie et al. · 2021 · The Journal of Experimental Medicine
57. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells
    Yuji Sakuma, Shoichi Matsukuma, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Shiro Koizume, Hironobu Sekiguchi, Haruhiro Saito, Haruhiko Nakayama, Yoichi Kameda, Tomoyuki Yokose et al. · 2013 · Laboratory Investigation
58. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
    Xin Zhang, Sudhir Raghavan, Michael A. Ihnat, Jessica E. Thorpe, Bryan C. Disch, Anja Bastian, Lora C. Bailey‐Downs, Nicholas F. Dybdal‐Hargreaves, C.C. Rohena, Ernest Hamel et al. · 2014 · Bioorganic & Medicinal Chemistry
59. Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF 1
    Juan Chen, Jieda Cui, Xiao‐tong Guo, Xia Cao, Qing Li · 2018 · Cancer Medicine
60. Erratum: Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association
    YC Yang, T-Y Cheng, S-M Huang, Chia‐Yi Su, P-W Yang, J-M Lee, C-K Chen, Michael Hsiao, K-T Hua, M-L Kuo · 2017 · Oncogene
61. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
    Xie, Caifeng, Jin, Jiangbo, Bao, Xujie, Zhan, Wei-Hua, Han, Tian-Yu, Gan, Mingxi, Zhang, Chengfu, Wang, Jianbin · 2016 · Oncotarget
62. A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine
    Johannes M. Heuckmann, Roman Kurt Thomas · 2015 · Annals of Oncology
63. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Soei Gen, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama et al. · 2022 · BMC Cancer
64. Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
    Junya Nakade, Shinji Takeuchi, Takayuki Nakagawa, Daisuke Ishikawa, Takako Sano, Shigeki Nanjo, Tadaaki Yamada, Hiromichi Ebi, Lu Zhao, Kazuo Yasumoto et al. · 2014 · Journal of Thoracic Oncology
65. Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
    Pengfei Ma, Yujie Fu, Minjiang Chen, Ying Jing, Jie Wu, Ke Li, Ying H. Shen, Jianxin Gao, Mengzhao Wang, Xiaojing Zhao et al. · 2016 · Theranostics
66. Epithelial‐to‐mesenchymal transition and its role in EGFR‐mutant lung adenocarcinoma and idiopathic pulmonary fibrosis
    Yuji Sakuma · 2017 · Pathology International
67. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors
    Yuji Sakuma, Yukiko Yamazaki, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Shoichi Matsukuma, Haruhiko Nakayama, Tomoyuki Yokose, Yoichi Kameda, Shiro Koizume, Yohei Miyagi · 2011 · Laboratory Investigation
68. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
    Yi-Qing Qu, Xiuxiu Wu, Yunhong Yin, Yan Yang, Dedong Ma, Hao Li · 2014 · Journal of Experimental & Clinical Cancer Research
69. Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase
    Eleonora Orlando, Daniel M. Aebersold, Michaela Medová, Yitzhak Zimmer · 2018 · Cancer Letters
70. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib
    U. Obst-Sander, Antonio Ricci, Bernd Kuhn, Thomas Friess, Philipp Koldewey, A. Kuglstatter, David S. Hewings, Annick Goergler, Sandra Steiner, Daniel Rueher et al. · 2022 · Journal of Medicinal Chemistry
71. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
    Valentina E. Schneeberger, Yuan Ren, Noreen Luetteke, Qingling Huang, Liwei Chen, Harshani R. Lawrence, Nicholas J. Lawrence, Eric B. Haura, John M. Koomen, Domenico Coppola et al. · 2015 · Oncotarget
72. Recent advances in targeted therapy for glioblastoma
    Shivani Arora Mittal, Shrikant N. Pradhan, Tapasya Srivastava · 2015 · Expert Review of Neurotherapeutics
73. Targeted biopharmaceuticals for cancer treatment
    Lufang Zhou, Ningning Xu, Yan Ping Sun, Margaret Liu · 2014 · Cancer Letters
74. Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies
    Georgios Tsakonas, Luigi De Petris, Simon Ekman · 2017 · Cancer Treatment Reviews
75. A panel of noncoding RNAs in non–small‐cell lung cancer
    Abouzar Bagheri, Hamid Reza Khorram Khorshid, Mahmood Tavallaie, Seyed Javad Mowla, Masih Sherafatian, Mohsen Rashidi, Mehryar Zargari, Mahdi Eskandarian Boroujeni, Sayed Mostafa Hosseini · 2018 · Journal of Cellular Biochemistry
76. Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
    Manzar Alam, Gulam Mustafa Hasan, Sayed M. Eldin, Mohd Adnan, Muhammad Bilal Riaz, Asimul Islam, Ilyas Khan, Md. Imtaiyaz Hassan · 2023 · Biomedicine & Pharmacotherapy
77. Effect of Phosphorylation on EGFR Dimer Stability Probed by Single-Molecule Dynamics and FRET/FLIM
    Oana Coban, Laura C. Zanetti-Domingues, Daniel R. Matthews, Daniel J. Rolfe, Gregory E. Weitsman, Paul R. Barber, Jody Barbeau, Viviane Devauges, Florian Kampmeier, Martyn Winn et al. · 2015 · Biophysical Journal
78. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun
    Ying Li, Zhiwei Yang, Weijie Li, Shudi Xu, Tao Wang, Ting Wang, Mengjie Niu, Shengli Zhang, Lintao Jia, Shengqing Li · 2016 · Oncotarget
79. Classification of Non-Small Cell Lung Cancer Based on Copy Number Alterations
    Biqing Li, Jin You, Tao Huang, Yu‐Dong Cai · 2014 · PLoS ONE
80. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas
    Jingshu Wang, Kun Zou, Feng Xu, Miao Chen, Cong Li, Ranran Tang, Xuan Yang, Meihua Luo, Wangbing Chen, Huijuan Qiu et al. · 2017 · Molecular Cancer
81. Anticancer Activity Evaluation of New Thieno[2,3-d]pyrimidin-4(3H)-ones and Thieno[3,2-d]pyrimidin-4(3H)-one Derivatives
    Olga Ya. Shyyka, Nazariy T. Pokhodylo, Nataliya S. Finiuk, V. S. Matiychuk, Rostyslav S. Stoika, Mykola D. Obushak · 2018 · Scientia Pharmaceutica
82. Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior
    Zaizai Dong, Shi Yan, Bing Liu, Yongcun Hao, Long Lin, Tianrui Chang, Hong Sun, Yusen Wang, Hu Li, Han Wu et al. · 2021 · Nano Letters
83. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
    Teresa Morán, Lecia Van Dam Sequist · 2012 · Journal of Clinical Oncology
84. Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
    Shigeki Nanjo, Tadaaki Yamada, Hiroshi Nishihara, Shinji Takeuchi, Takako Sano, Takayuki Nakagawa, Daisuke Ishikawa, Lu Zhao, Hiromichi Ebi, Kazuo Yasumoto et al. · 2013 · PLoS ONE
85. Advances in Gas Chromatographic Methods for the Identification of Biomarkers in Cancer
    Konstantinos A. Kouremenos, Mikael Johansson, Philip John Marriott · 2012 · Journal of Cancer
86. EGFR inhibitors and autophagy in cancer treatment
    Jie Cui, Yunfeng Hu, Xie-Min Feng, Tao Tian, Yahuan Guo, Junwei Ma, Kejun Nan, Hongyi Zhang · 2014 · Tumor Biology
87. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
    Yosef Yarden, Deric L. Wheeler · 2014 · Springer eBooks
88. Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
    Jing Huang, Yiyin Wang, Yachao Zhai, Jin Wang · 2018 · Thoracic Cancer
89. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
    Andreas Ioannis Papadakis, Chong Sun, Theo Knijnenburg, Yibo Xue, Wipawadee Grernrum, Michael Hölzel, Wouter Nijkamp, Lodewyk F.A. Wessels, Roderick L. Beijersbergen, René Bernards et al. · 2015 · Cell Research
90. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
    Guanghui Cui, Donglei Liu, Weihao Li, Xiao Fu, Youguang Liang, Yuhang Li, Wensong Shi, Xiaofang Chen, Song Q Zhao · 2017 · Medicine
91. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors
    Ludovic Ménard, Nicolas Floc’h, Matthew J. Martin, Darren A.E. Cross · 2018 · Cancer Research
92. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
    Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha, Seetharama D. S. Jois · 2019 · Current Medicinal Chemistry
93. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET
    Ha‐Na Oh, Mee-Hyun Lee, Eunae Kim, Goo Yoon, Jung‐Il Chae, Jung‐Hyun Shim · 2019 · Phytomedicine
94. An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis
    Suzie K. Hight, Allison A. Mootz, Rahul Krishna Kollipara, Elizabeth A. McMillan, Paul M. Yenerall, Otaki Yoichi, Long-Shan Li, Kimberley Avila, Michael Peyton, Jaime Rodriguez‐Canales et al. · 2020 · Neoplasia
95. Lung cancer and epithelial-mesenchymal transition
    Toshi Menju, Hiroshi Date · 2021 · General Thoracic and Cardiovascular Surgery
96. Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Zhenfang Du, Hongfei Kan, Jinghan Sun, Yue Liu, Jiahui Gu, Shugela Akemujiang, Yudi Zou, Lufan Jiang, Q Wang, Chen Li et al. · 2025 · Drug Resistance Updates
97. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study
    Emilio Esteban, Margarita Majem, Maite Martínez Aguillo, Natividad Martínez-Banaclocha, Manuel Dómine, Lorenzo Gómez-Aldaraví, Óscar Juan, R. Cajal, M. C. González Arenas, Mariano Provencio · 2015 · Cancer Epidemiology
98. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells
    Giulia Maria Stella, Roberta Scabini, Simona Inghilleri, Francesca Cemmi, Simona Corso, Ernesto Pozzi, Patrizia Morbini, Adele Valentini, Roberto Dore, Simona Ferrari et al. · 2013 · Journal of Cancer Research and Clinical Oncology
99. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?
    Chao‐Hua Chiu, Teh‐Ying Chou, Chi‐Lu Chiang, Chun‐Ming Tsai · 2014 · Cancer Chemotherapy and Pharmacology
100. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
     Sahil Hussain, Mohd Mursal, Garima Verma, S. S. Hasan, Mohemmed Faraz Khan · 2024 · European Journal of Pharmacology